Status:
COMPLETED
Repeatability and Response Study of Absorptive Clearance Scans
Lead Sponsor:
Tim Corcoran
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The investigators are developing a new nuclear medicine imaging technique for measuring liquid absorption in the airways that can be applied to screen new medications being developed to treat cystic f...
Detailed Description
Cystic Fibrosis (CF) is an autosomal recessive genetic disease, caused by mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) that impairs ion transport at epithelial surfaces....
Eligibility Criteria
Inclusion
- subjects 18 years old or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator
Exclusion
- one second forced expiratory volume (FEV1) \<50% of predicted
- nursing mother
- positive urine pregnancy test or unwilling to test
- cigarette smoker
- unwilling to stop hypertonic saline therapy for 72 hours prior to each test day
- are intolerant to hypertonic saline (response only)
- are intolerant to any inhaled therapies (response only)
- fail mannitol tolerance testing (response only)
- have a history of excessive (uncontrollable) coughing after an osmotic stimulus (response only)
- have a history of hemoptysis (response only)
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2018
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01887197
Start Date
June 1 2013
End Date
May 1 2018
Last Update
November 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213